health
health · EN · 56 episodes
Lan-Lan Smith, Editor-in-Chief, Emma Cookson, Deputy Editor, and Daniela Marín, Senior Editor at The Lancet Haematology, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.A monthly audio companion to the journal, this podcast covers a broad range of topics, from racial and ethnic disparities in leukaemia survival outcomes to resuscitation with blood products compared with saline, the link between mental health and lymphoma to haemolytic disease in newborns, and more.
Required Pod Score for this show. PitchCentric checks your profile against host openness, topical fit, and audience signals before you generate a pitch.
Contact path
Public web form
Booking probability
31%
Guest openness
Selective
Sign up to generate a grounded pitch for The Lancet Haematology in conversation with.
Signup to Generate a PitchLan-Lan Smith, Editor-in-Chief, Emma Cookson, Deputy Editor, and Daniela Marín, Senior Editor at The Lancet Haematology, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.A monthly audio companion to the journal, this podcast covers a broad range of topics, from racial and ethnic disparities in leukaemia survival outcomes to...
Recent episodes include "Thalassaemia revisited: from health burden to breakthroughs" (6 October 2026, 48 minutes), "Adverse event reporting in haematological malignancies with the authors of our Adverse Events Series" (27 August 2026, 36 minutes), and "Bethany Samuelson Bannow and Maureen Achebe on classical haematological disease in women" (6 August 2026, 24 minutes).
The Lancet Haematology in conversation with publishes roughly monthly, with episodes averaging 21 minutes across 56 episodes.
Booking probability for The Lancet Haematology in conversation with is 31%, and the host is rated Selective on guests. The Lancet Haematology in conversation with requires a Pod Score of 80 or higher. The Lancet Haematology in conversation with's contact route on record: public web form.
The strongest fits for The Lancet Haematology in conversation with are Health & Wellness Services. The Lancet Haematology in conversation with has a health audience.
The Lancet Haematology in conversation with is a health show with 56 episodes published.
Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.
Episode #7
Thalassaemia care is advancing fast, from gene therapies to AI diagnostics, but access and prevention still lag behind. Hear from the authors of The Lancet Haematology's "Thalassaemia revisited: from health burden to...
Episode #6
Blood cancer treatments are advancing fast — but so are their side effects. Hear from the authors of The Lancet Haematology's Adverse Event reporting series on better trial design, patient-centric care, and what part 2...
Episode #5
Dr Lan-Lan Smith joined the lead author of our latest Commission Dr Bethany Samuelson Bannow and author Dr Maureen Achebe to discuss classical haematological disease in women with Dr Julia Sandrin Gauer from the...
Episode #4
<p>Most previous patient-reported outcome results for CAR T-cell therapy have come from clinical trials testing these treatments, but information on how patients experience this treatment in real-world settings is...
Episode #3
<p>Dr Carmelo Gurnari joins us to discuss the development of recommendations from the EBMT Practice Harmonisation and Guidelines Committee on diagnosis, prevention, treatment, and donor management of donor cell-derived...
Episode #2
<p>Dr Penelope Stein joins us to discuss the development of new international guidelines for the diagnosis, management, and treatment of the rare, genetically-linked condition, acute prophyria.</p> <p>Click here to read...
The Lancet Haematology in conversation with
<p>Professor Marc Riedl joins us to discuss two trials testing oral deucrictibant for hereditary angioedema attacks: one testing deucrictibant as on-demand therapy to treat attacks and the other testing deucrictibant...
The Lancet Haematology in conversation with
<p>Dr Julio Delgado and Dr Valentín Ortiz-Maldonado join us to discuss the results of their phase 2 trial testing varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic...
The Lancet Haematology in conversation with
<p>Dr Julio Delgado and Dr Valentín Ortiz-Maldonado join us to discuss the results of their phase 2 trial testing varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic...
The Lancet Haematology in conversation with
<p>Dr Erica Kaye and Dr Dylan Graetz join us to discuss the importance of qualitative research and how the whole research ecosystem can incorporate and support this type of research to help set the right research...
The Lancet Haematology in conversation with
<p>Professor Isabelle Mahé joins us to discuss the results of a post-hoc analysis of the API-CAT trial identifying predictors associated with clinically relevant bleeding during extended anticoagulation for...
The Lancet Haematology in conversation with
<p>Arnon Kater joins Daniela Marin of The Lancet Haematology to discuss the phase 1b/2 EPCORE CLL-1 trial of epcoritamab monotherapy for Richter transformation, which is being presented at ASH 2025.</p> <p>Click here to...
The Lancet Haematology in conversation with
<p>Khaled Musallam, Bethany Samuelson Bannow, Mohamad Mohty, David Sallman, and Anna Sureda join us to share their expectations for the upcoming ASH 2025 congress, to be held from 6 to 9 December 2025 in Orlando, on...
The Lancet Haematology in conversation with
<p>Professor Arnon Kater and Dr Sabina Kersting join us to discuss the results of their phase 2 trial testing a new first-line treatment regimen in chronic lymphocytic leukaemia: fixed-duration ibrutinib–venetoclax...
The Lancet Haematology in conversation with
<p>Dr. Ruben Mesa (Executive Director of the Wake Forest Baptist Comprehensive Cancer Center) joins us to discuss the results of a multicentre, open-label, randomised, active-controlled, phase 3 study of ropeginterferon...
The Lancet Haematology in conversation with
<p>Today, on World Lymphoma Awareness Day, Professors Yok Lam Kwong, Wee Joo Chng, and Eric Tse join us in this joint episode of The Lancet Haematology and The Lancet Regional Health - Western Pacific to discuss their...
The Lancet Haematology in conversation with
<p>June has been packed with interesting haematology conferences so the editorial team behind The Lancet Haematology have gathered to share their thoughts and reflect on their experiences at the European Hematology...
The Lancet Haematology in conversation with
<p>Associate Professor Paolo Strati (Department of Lymphoma and Myeloma, and Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA) joins us to discuss the...
The Lancet Haematology in conversation with
<p>With a growing number of treatment options for blood cancers, understanding the side effects from these treatments and how they affect patients is becoming ever more important. Join a panel of authors from The Lancet...
The Lancet Haematology in conversation with
<p>Dr Michael Northend (University College London Hospitals NHS Foundation Trust, and Cancer Research UK & UCL Cancer Trials Centre, London, UK) joins us to discuss the long-term results of a randomised, phase 3 trial...
Recent guests on The Lancet Haematology in conversation with. Study who booked and why before you pitch.
Trauma-Informed Life Coach and Business Consultant
Lead BI Engineer, CoinDcx
The Lancet Haematology
EBMT Practice Harmonisation and Guidelines Committee
PitchCentric classifies The Lancet Haematology in conversation with under these industries. Guests from them are the closest fit, and each links to the best podcasts in that industry.
Is this podcast yours and you'd like to remove or correct details? Request removal or email privacy@pitchcentric.com.
Questions about the free trial? See the pricing FAQ